A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients
Status:
RECRUITING
Trial end date:
2025-09-25
Target enrollment:
Participant gender:
Summary
The study will be a single center, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, PK and PD of AP303 following 2-week oral administration to Diabetic Kidney Disease patients.